Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 525.9% in May

Sunshine Biopharma, Inc. (NASDAQ:SBFMGet Rating) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 1,660,000 shares, an increase of 525.9% from the April 30th total of 265,200 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is presently 1.3 days. Currently, 9.2% of the company’s shares are short sold.

Sunshine Biopharma Price Performance

Sunshine Biopharma stock traded up $0.00 during trading hours on Friday, reaching $0.59. The stock had a trading volume of 141,643 shares, compared to its average volume of 939,707. Sunshine Biopharma has a 52 week low of $0.45 and a 52 week high of $1.85. The company has a fifty day simple moving average of $0.67 and a 200-day simple moving average of $0.79.

Institutional Investors Weigh In On Sunshine Biopharma

Large investors have recently modified their holdings of the stock. Two Sigma Investments LP purchased a new position in Sunshine Biopharma during the 3rd quarter valued at about $29,000. Virtu Financial LLC raised its holdings in shares of Sunshine Biopharma by 242.8% during the second quarter. Virtu Financial LLC now owns 47,861 shares of the company’s stock valued at $52,000 after purchasing an additional 33,898 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Sunshine Biopharma during the second quarter valued at approximately $40,000. Finally, Jane Street Group LLC bought a new stake in Sunshine Biopharma during the first quarter valued at approximately $31,000. Institutional investors own 18.29% of the company’s stock.

Sunshine Biopharma Company Profile

(Get Rating)

Sunshine Biopharma, Inc is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm’s product include treatment for Coronavirus infections and anticancer drugs.

Further Reading

Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with's FREE daily email newsletter.